Submitted:
05 June 2020
Posted:
07 June 2020
Read the latest preprint version here
Preprints on COVID-19 and SARS-CoV-2
Abstract
Neuroinflammation, defined as inflammatory reactions mediated by cytokines, chemokines, reactive oxygen species, and secondary messengers in the central nervous system (CNS) including the brain and spinal cord is the basis of many neurological disorders [1] Recently, erythropoietin (EPO) has been considered and studied as a modulator of neuroinflammation.[2-4] On this article minireview of pathophysiology of neuroinflammation and the neuroprotective effects of EPO is discussed and a case of subacute huge subdural hematoma with double mydriasis operated urgently, treated with low daily dose (vs high dose once or twice a month in the literature) of EPO and recovered fully and discharged home with good consciousness is reported. In addition, the probable outcome of erythropoietin administration in patients with neuroinflammation in COVID19 is considered.
Keywords:
Ang II
; COVID19
; erythropoietin
; EPO-R
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
